Trichomegaly following treatment with interferon alpha-2b

Hernández‐Núñez, A.; Fernández‐Herrera, Jesús; Buceta, L. Ríos; García‐Diez, Amaro

doi:10.1016/s0140-6736(02)08153-9

Cited by 30 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This side effect is more likely to be related with biochemical abnormalities in pheomelanin synthesis rather than with immunological disorders since none of our patients with hair discoloration experienced vitiligo at the same time, contrasting with the patient described by Bernstein et al [9]. Straight hair [10], trichomegaly [11]or alopecia areata [12], already described with interferon therapy, were not observed in our series.…”

Section: Discussioncontrasting

confidence: 63%

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

et al. 2004

View full text Add to dashboard Cite

Introduction: α-Interferon is associated with numerous cutaneous side effects, but the accurate incidence of these complications is not clearly known. Objectives: A prospective study was designed to evaluate the incidence and clinical pattern of cutaneous side effects in a cohort of patients receiving adjuvant therapy with low-dose interferon for malignant melanoma. Material and Methods: A cohort of 33 patients with stage IIA and IIB melanoma treated with low-dose α-interferon (3 MIU 3 times a week for 18 months) were prospectively enrolled in a single-center study. The patients responded to a questionnaire on their medical history and were systematically examined for any cutaneous lesions before treatment and every 3 months afterwards. Results: 29/33 patients (87%) experienced 1 or more cutaneous side effects. The most frequent was hair loss and occurred in 16 cases (48.4%). Hair discoloration was noted in 6 cases (18%). Eczematous reactions at injection sites or at remote sites were observed in 13 patients (39%). Pruritus occurred in 10 cases (30%). Xerostomia, Raynaud’s phenomenon or livedo reticularis were observed in 10 patients, associated with an increase in circulating autoantibody titer in 2 cases. Some rare side effects were observed: urticaria (1 case) or angioedema (1 case), worsening of preexisting seborrheic dermatitis (3 cases), herpetic recurrence (2 cases), pityriasis versicolor (1 case), worsening of recurrent buccal aphthous ulcer (1 case) and vitiligo (1 case). Conclusion: Cutaneous adverse events during adjuvant immunotherapy of melanoma with low-dose α-interferon seem to be frequent but do not result in treatment discontinuation. A good awareness of these side effects may be useful for a more accurate survey and clinical management of patients receiving this treatment.

show abstract

Section: Discussioncontrasting

confidence: 63%

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

et al. 2004

View full text Add to dashboard Cite

show abstract

“…32 Trichomegaly developed after treatment with interferon-␣ in patients with chronic hepatitis, 33 B-cell lymphoma, 34 chronic granulocytic leukemia, 35 and cutaneous melanoma. 36 Four patients showed eyelash hypertrichosis after 3 to 4 months of treatment with systemic cyclosporine. 37 They had received renal allograft (2 patients) or liver allograft (1 patient) or experienced severe thrombocytopenia (1 patient).…”

Section: Discussionmentioning

confidence: 96%

Long Eyelashes in a Case Series of 93 Children With Vernal Keratoconjunctivitis

et al. 2005

View full text Add to dashboard Cite

ABSTRACT. Objective. Vernal keratoconjunctivitis (VKC) is a chronic conjunctivitis that affects children mainly in temperate areas, with exacerbations in spring and summer. Eyelashes provide natural protection for the eyes from sunshine, wind, and foreign bodies. These factors induce a worsening of signs and symptoms in VKC, whereas mechanical protection of the eyes produces relief. The aim of this study was to evaluate eyelash length in a large series of VKC patients and in ageand gender-matched healthy subjects.Methods. Upper eyelash length was measured in 93 VKC patients (mean age: 8.7 years; range: 4 -18 years) with a digital caliper. History, clinical form, type of presentation, degree of severity, and drug therapy were evaluated. Skin tests and serum-specific immunoglobulin E for common allergens, serum-total immunoglobulin E, peripheral blood eosinophil counts, and serum eosinophil cationic protein were determined. Two age-and gender-matched control subjects for each VKC patient underwent the same eyelash measurement.Results. The upper eyelashes were significantly longer in VKC patients than in control subjects (mean ؎ SD: 8.9 ؎ 1.17 mm vs 7.9 ؎ 1.07 mm). In healthy subjects, a negative correlation was found between eyelash length and age. With multivariate analysis, unlike control subjects, the eyelash length in VKC patients did not correlate with age, was positively correlated with the degree of severity of VKC, and was negatively correlated with the use of topical cyclosporine.Conclusions. Patients with VKC had longer eyelashes than healthy matched subjects. ABBREVIATIONS. VKC, vernal keratoconjunctivitis; bFGF, basic fibroblast growth factor; s-P, substance P; IgE, immunoglobulin E; s-ECP, serum eosinophil cationic protein; PBEC, peripheral blood eosinophil count.

show abstract

“…Cutaneous side‐effects to IFN‐α have been reported: 1–5 mild reversible alopecia, local reactions, psoriasis, systemic lupus erythematosus, eosinophilic fasciitis, paraneoplastic pemphigus, leucocytoclastic vasculitis and trichomegaly.…”

Section: Introductionmentioning

confidence: 99%

Livedo reticularis associated with interferon α therapy in two melanoma patients

Ruíz‐Genao

García‐F‐Villalta

Hernández‐Núñez

et al. 2005

Acad Dermatol Venereol

View full text Add to dashboard Cite

We report two patients who developed intense livedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma. Histological studies showed scattered perivascular infiltrates without vasculitis. Laboratory tests excluded any underlying condition. Resolution of the symptoms was observed in both patients when interferon alpha was withdrawn. These cases highlight the occurrence of livedo reticularis as an uncommon side-effect of interferon alpha treatment.

show abstract

Trichomegaly following treatment with interferon alpha-2b

Cited by 30 publications

References 0 publications

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma

Long Eyelashes in a Case Series of 93 Children With Vernal Keratoconjunctivitis

Livedo reticularis associated with interferon α therapy in two melanoma patients

Contact Info

Product

Resources

About